Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline Alfoscerate in MCI with Cerebrovascular Disease
NCT05050604Phase 4Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in vascular cognitive impairment (VCI) comparing Choline Alfoscerate with Placebo (2 arms). Primary endpoint: The proportion of subjects whose cognitive function is maintained/improved at 48 weeks. Status: unknown.
02
Drugs
choline alfoscerate
03
Conditions
vascular cognitive impairment (VCI)
Beyond the preview
Go deeper on NCT05050604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050604.